<DOC>
	<DOCNO>NCT01538329</DOCNO>
	<brief_summary>Traditionally amantadine use begin Parkinson Disease ( PD ) treatment early stage disease , modest antiparkinsonian symptomatic treatment . This treatment usually maintain first month management , resort drug deem effective dopamine agonists lévo-DOPA ( L-DOPA ) . A modern use drug advance stage PD dyskinesia already establish become disabling patient . There data two extreme life stage Parkinsonism . However , mechanisms action amantadine pathophysiology motor complication induce L-DOPA , particular dyskinesia suggest early prolong use amantadine early year management , L-DOPA-induced dyskinesia already emerge , positive impact long-term occurrence fate symptom , possibly glutamatergic mechanism brain plasticity-of `` disease modification '' type . The primary purpose study demonstrate early introduction treatment amantadine ( 200 mg / ) early year therapeutic care , say `` honeymoon '' levodopa ( early phase disease &lt; 3 year diagnosis &lt; 1 year L-dopa lack complication levodopa therapy ) decrease rate subject abnormal involuntary dyskinetic movement 18 month follow-up .</brief_summary>
	<brief_title>Amantadine L-DOPA-induced Dyskinesia Early Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Age 35 year , Patients sign informed consent specific study procedure , Patients health Insurance Coverage ( accord local regulatory requirement ) , Patients suffer idiopathic Parkinson 's disease meeting definition criterion UKPD Brain Bank ( Gibb Lees , 1988 ) , Parkinson 's disease diagnose &lt; 3 year , Patients receive treatment LDOPA &lt; 1year , Lack complication levodopa therapy Patients receive stable antiparkinsonian treatment may involve , addition LDOPA , dopamine agonist , monoamine oxidaseB ( MAOB ) catecholamine Omethyl transferase ( COMT ) inhibitor , anticholinergic least 2 month enrollment presume possible maintain treatment unchanged study period ( except dose Ldopa adjust study third month Phase 1 ) . Atypical parkinsonian syndrome , Druginduced Parkinsonism , Juvenile Parkinson , Patients complication levodopa therapy Inability keep current stable antiparkinsonian treatment study period , apart LDOPA , Pretreatment amantadine , amantadine counterindication Neuroleptic treatment , Patients dementia , Mini Mental Status ( MMS ) &lt; 26 , Patient behavioral disorder , ECMP item ≥ 3 Female subject childbearing potential without effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Dyskinesia</keyword>
	<keyword>L-DOPA</keyword>
	<keyword>Early introduce treatment</keyword>
	<keyword>Amantadine</keyword>
</DOC>